Recombinant IFN-γ from the bank vole Myodes glareolus: a novel tool for research on rodent reservoirs of zoonotic pathogens by Torelli, Francesca et al.
1SCIENTIFIC REPORTS |  (2018) 8:2797  | DOI:10.1038/s41598-018-21143-0
www.nature.com/scientificreports
Recombinant IFN-γ from the bank 
vole Myodes glareolus: a novel tool 
for research on rodent reservoirs of 
zoonotic pathogens
Francesca Torelli1, Steffen Zander1, Heinz Ellerbrok2, Georg Kochs3, Rainer G. Ulrich4, 
Christian Klotz1 & Frank Seeber1
Rodent species like Myodes glareolus and Microtus spp. are natural reservoirs for many zoonotic 
pathogens causing human diseases and are gaining increasing interest in the field of eco-immunology 
as candidate animal models. Despite their importance the lack of immunological reagents has 
hampered research in these animal species. Here we report the recombinant production and functional 
characterization of IFN-γ, a central mediator of host’s innate and adaptive immune responses, from 
the bank vole M. glareolus. Soluble dimeric recMgIFN-γ was purified in high yield from Escherichia coli. 
Its activity on M. glareolus and Microtus arvalis kidney cell lines was assessed by immunofluorescent 
detection of nuclear translocation and phosphorylation of the transcription factor STAT1. RecMgIFN-γ 
also induced expression of an IFN-γ-regulated innate immunity gene. Inhibition of vesicular stomatitis 
virus replication in vole cells upon recMgIFN-γ treatment provided further evidence of its biological 
activity. Finally, we established a recMgIFN-γ-responsive bank vole reporter cell line that allows the 
sensitive titration of the cytokine activity via a bioluminescence reporter assay. Taken together, we 
report valuable tools for future investigations on the immune response against zoonotic pathogens in 
their natural animal hosts, which might foster the development of novel animal models.
Rodents are a major reservoir of zoonotic pathogens, which cause nearly 60% of human infectious diseases1. 
These infectious agents pose a public health threat to humans and livestock alike2. Besides the widely studied 
house mouse Mus musculus and the Norway rat Rattus norvegicus other rodent species have a crucial role as 
carriers of pathogens in the wild. Within the same family Muridae this includes the wood mouse A. sylvaticus 
and within the family Cricetidae the deer mouse Peromyscus maniculatus, the bank vole Myodes glareolus and the 
common vole Microtus arvalis (called “non-murine rodents” further on). For named species genome sequences 
are available, thus allowing detailed molecular and immunological studies. The importance of voles as host spe-
cies for pathogens is emphasised by our own analysis of data from a recent report showing that out of 217 rodent 
species known to be reservoirs for zoonotic pathogens, 43 (19.8%) belong to these four genera3 (Supplementary 
Fig. S1). Furthermore, in the respective study, modelling suggested that out of 57 rodent species predicted to be 
reservoirs for future zoonoses, 16 (28%) are vole species.
Of these rodent species the bank vole has attracted increased attention for being the main host for Puumala 
orthohantavirus (PUUV), one of the most important hantaviruses in Europe. In these voles infection with PUUV 
is thought to be almost asymptomatic whereas it usually provokes a mild to moderate form of hemorrhagic fever 
with renal syndrome (HFRS) in humans, occasionally with fatal outcome4. Recent studies suggest that the bank 
vole is a reservoir not only for tick-borne encephalitis virus but also for cowpox virus, a pathogen increasingly 
reported to cause infection in humans5–7. In addition, bacteria such as Leptospira spp., Bartonella spp., Rickettsia 
spp., Borrelia spp. and unicellular eukaryotic parasites like Giardia spp., Cryptosporidium spp., Babesia microti 
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and Toxoplasma gondii are just some of the pathogens identified in non-murine rodents8–13. Thus, voles and other 
rodents are important carriers of pathogens but are largely understudied.
Non-murine rodents have also found increased interest in the field of wild- or eco-immunology. The lab-
oratory M. musculus system is often a choice based on convenience rather than closeness to the natural situa-
tion and its value has been largely questioned, especially in the context of translational research14. Therefore, 
non-murine rodent models are gaining increased attention since they are natural reservoirs of many zoonotic 
pathogens and carriers of the genetic variability lost in inbred mouse colonies15,16. The lack of crucial reagents 
like species-specific cytokines greatly hampers their more widespread use, but recent availability of genomic and 
transcriptomic data17,18 make immunological studies feasible also for non-murine rodents19.
Interferon γ (IFN-γ) is one of the main cytokines regulating immunity and inflammation. Its eminent role 
in Th1 immune responses, macrophage activation, autoimmunity, host defense against intracellular pathogens 
and modulation of the adaptive immunity is well understood20. IFN-γ binds as a homodimer to its cell surface 
receptor –composed of subunits IFN- γR1 and IFN- γR2– leading to subsequent activation of the Janus Kinase 
(JAK)-mediated signal transduction pathway21. Signal transducer and activator of transcription 1 (STAT1) is 
the main transcription factor that is activated by engagement of the IFN-γ receptor. Phosphorylation of tyrosine 
701 (Tyr701) and subsequent dimerization of STAT1 leads to its nuclear translocation where it can induce the 
expression of several target genes22 via binding to the interferon-Gamma Activator Sequence (GAS) in their 
promoter region. For its maximal transcriptional activity, phosphorylation of serine 727 (Ser727), mediated by 
the Mitogen-Activated Protein (MAP) kinase pathway, is also needed23. In mice, the family of Immunity Related 
GTPase (IRG) genes is among the many induced by IFN-γ24. The corresponding large group of IRG proteins reg-
ulates cell-autonomous antimicrobial responses of the host following infection by intracellular pathogens like the 
bacterium Chlamydia trachomatis or the protozoan T. gondii25,26. IFN-γ is also a major mediator of the immune 
response against many viruses, including vesicular stomatitis virus (VSV)27,28.
While signalling via the IFN-γ pathway is conserved among different organisms, the cytokine and its receptors 
are species-specific and show no or only little cross-reactivity29. Consequently, in most cases the homologous pro-
tein is needed when experimentally working with a given vertebrate species. For less studied species commercial 
IFN-γ sources are scarce or not available and in all those cases cloning of its coding sequence and production of 
the protein is needed for experimental work. Here we report the generation and functional characterization of 
recombinant IFN-γ of the bank vole M. glareolus.
Results and Discussion
Limited sequence conservation of IFN-γ between different rodent species and its implication 
for activity. The known species-specific activity of IFN-γ is reflected by diversity at the protein sequence 
level29. We compared available IFN-γ genomic sequences of various rodents with that of Homo sapiens for com-
parison (Fig. 1a). The cluster with the highest degree of amino acid sequence conservation is represented by 
the arvicoline species Microtus ochrogaster, M. agrestis, Ellobius lutescens and M. glareolus, with more than 90% 
sequence identity over the entire sequence, followed by the murine cluster with M. musculus, A. sylvaticus and R. 
norvegicus (Fig. 1a). In contrast there is a high divergence between murid and arvicoline clusters, with M. muscu-
lus and M. glareolus sharing only 57.3% amino acid sequence identity.
At the protein level high sequence conservation of IFN-y exists between species in streches corresponding to 
core regions of the protein (underlined areas in Fig. 1b) whereas it is lower outside of the same phylogenetic clade. 
In particular, certain residues previously implicated in the binding of IFN-γ with the receptor (IFN-γR1)29 have a 
high degree of sequence divergence between murid and cricetid rodents (red boxes in Fig. 1b).
A further obvious difference is the C-terminal extension of the IFN-γ sequence of cricetid rodents as well as 
of humans compared to that of murid rodents (Fig. 1b). The basic lysine and arginine-rich stretch, located at the 
carboxy-terminal end of murine IFN-γ (Fig. 1b; “basic stretch”), is highly conserved in all IFN-γ sequences and 
has also been implicated in receptor binding29,30. It is interesting to note that carboxy-terminal deletion mutants 
(up to 10 aa) of recombinant human IFN-γ up to the basic stretch showed higher antiviral activity than the 
corresponding wild-type cytokine31–34. This enhanced activity was attributed to a higher thermal stability of the 
truncated protein, measured by circular dichroism analysis33. It is tempting to speculate that the extension beyond 
the basic stretch has evolved differently in different species to allow fine-tuning of the interaction between IFN-γ 
and its specific receptor molecules and thus cellular activation.
Taken together, there is low sequence conservation between murid and cricetid sequences and we anticipated 
and confirmed (see below) that commercial mouse IFN-γ would be active on mouse and murid cells but not on 
cells of vole species. Therefore, heterologous expression of M. glareolus recombinant IFN-γ (recMgIFN-γ) was 
attempted in Escherichia coli.
Production of dimeric recombinant MgIFN-γ in E. coli. Based on a deposited MgIFN-γ sequence 
(GenBank HQ650825) an E. coli expression vector was designed that allowed the recombinant expression 
of MgIFN-γ as a C-terminally 6His-tagged protein (recMgIFN-γ). Expression was robust, yielding gener-
ally > 3 mg/L of soluble protein after a single round of purification by immobilised metal affinity chromatography. 
SDS-PAGE analysis of the purified protein showed three major bands (20, 42 and 65 kDa; inferred from a stand-
ard curve based on the MW markers) and two minor bands (15 and > 100 kDa; Fig. 2a). The four largest proteins 
reacted with an anti-6His antibody and are interpreted as monomer, dimer, trimer and higher order aggregates. 
Such aggregates are known to occur with recIFN-γ under non-native conditions35–38, as is e.g. the case during 
SDS-PAGE. Their molecular masses are in good agreement with the calculated MW of monomeric recMgIFN-γ 
containing a 6His-tag (18.3 kDa).
The bacterial strain OmniMax 2T1R (containing the outer membrane protease OmpT) provided better 
expression results than the OmpT-deficient strain BL21 in our hands. However, OmpT is known to cut within the 
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C-terminal stretch of basic amino acids of H. sapiens IFN-γ39,40 resulting in the frequently observed truncated, 
but otherwise stable ca. 15–16 kDa version of E. coli-derived IFN-γ33,39. In different preparations the small 15 kDa 
protein not reactive with an anti-6His antibody was inconsistently seen. We therefore assume that this protein is a 
C-terminal degradation product and is co-purified by dimer formation with a 6His-tagged monomer.
Since IFN-γ needs to be in a homodimeric form to activate its receptor we analyzed purified recMgIFN-γ by 
gel filtration on a calibrated analytical Superdex 75 column to determine the proportion of the dimeric form in 
our preparations. As shown in Fig. 2b, the vast majority of the applied protein eluted at a column volume which 
is consistent with the dimeric form (36.4 kDa observed vs. 36.6 kDa calculated). The peaks at around 20 kDa and 
62 kDa presumably represent monomeric and trimeric forms, and the peak >80 kDa higher order aggregates, 
respectively (column resolution is up to 70–80 kDa). Collectively, these results show that a single affinity chro-
matography purification of recMgIFN-γ resulted in a large proportion of soluble, dimeric and thus presumably 
correctly folded and active protein.
recMgIFN-γ activates STAT1 signaling in vole cell lines. When IFN-γ activates its signaling pathway 
phosphorylation of cytosolic STAT1 and its subsequent nuclear translocation is observed22. This signalling cas-
cade and the molecules involved are highly conserved between species and present even in fish41. We therefore 
Figure 1. Protein sequence diversity of IFN-γ within rodent species. (a) Amino acid sequence similarity (in 
percentage) of IFN-γ proteins. On the left, a taxonomic species tree is shown, whereby Peromyscus maniculatus 
and H. sapiens served as more distant species for comparison. The Arvicolinae (red branches) and the Murinae 
species (blue branches) are indicated. (b) IFN-γ amino acid sequence comparison between different rodent 
species and H. sapiens. Light blue indicates lower percentage of identity than dark blue. Arrow head indicates 
the M. musculus signal peptide cleavage site. Residues involved in the binding to the receptor subunit IFN-γR1 
are highlighted by red boxes. Functionally important regions and the C-terminal basic domain are indicated29.
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assessed co-localization of phospho-Tyr701-STAT1 with cell nuclei of treated cells by immunofluorescent assay 
(IFA) with a rabbit anti-phospho Tyr701-STAT1 antibody (similar to a previous study on bank voles42) on differ-
ent cell lines (Table 1).
M. musculus NIH/3T3 cells treated with the homologous mouse IFN-γ showed nuclear-localised and phos-
phorylated Tyr701-STAT1 (Fig. 3). No signal was detected in either untreated NIH/3T3 cells or cells treated with 
recMgIFN-γ. As expected from the low IFN-γ sequence similarity between murine and vole species, following 
treatment of the M. glareolus kidney cell line BVK168 with mouse IFN-γ we observed no nuclear signal, like in 
untreated cells (Fig. 3). In contrast, a clear co-localization of phosphorylated Tyr701-STAT1 and cell nuclei was 
detected in BVK168 cells following recMgIFN-γ treatment. Furthermore, recMgIFN-γ but not mouse IFN-γ was 
active on a M. arvalis kidney cell line (FMN-R). Moreover, in a cell line (AAL-R) from A. agrarius mouse IFN-γ 
activated phosphorylation and nuclear translocation of STAT1 in this related murine species, confirming our 
predictions from sequence analysis.
Since full transcriptional activity of STAT1 also requires Ser727 being phosphorylated23, we assessed its sta-
tus by an anti-mouse phospho-Ser727-STAT1 antibody in NIH/3T3, BVK168 and AAL-R cell lines. The IFA 
data mirrored the results of Tyr701 and confirmed Ser727 of STAT1 being also phosphorylated (Supplementary 
Fig. S2). Together these results provided first evidence of species-specific recMgIFN-γ cellular activity. These 
experiments also showed the usefulness of selected reagents (see Supplementary Table S2) for this purpose, i.e. 
phosphorylation-specific monoclonal antibodies for STAT1, and proved activity of the mouse IFN-γ on a striped 
field mouse cell line.
recMgIFN-γ induces upregulation of an IFN-γ inducible gene. IFN-γ pathway activation leads to 
STAT1-mediated expression of numerous target genes, such as the IRG gene family in rodents43. Due to our inter-
est in this innate immune response gene family during infection with the protozoan parasite T. gondii44 we chose 
to measure the increase of mRNA of one of its members, Irgb2-b1, by real-time quantitative Reverse Transcription 
PCR (qRT-PCR) as a further proof of recMgIFN-γ activity. The test was performed on BVK168 and FMN-R cells. 
We compared Irgb2-b1 expression in cells treated with either recMgIFN-γ, murine IFN-γ, a control protein (a 
T. gondii protein of similar size called LEA) purified from the same E. coli cells under identical conditions as 
recMgIFN-γ, or left untreated. As reference gene for normalization we chose the tyrosine 3-monooxygenase/tryp-
tophan 5-monooxygenase activation protein zeta gene (Ywhaz), which was previously shown to be a reliable gene 
for this purpose in the closely related field vole M. agrestis45. Following recMgIFN-γ treatment a dose-dependent 
relative increase in Irgb2-b1 mRNA levels in both vole cell lines was observed, which reached 8-fold when 200 
ng/ml protein was used, compared to untreated cells or cells treated with the control protein LEA (Fig. 4). The 
latter confirmed a recMgIFN-γ-specific effect on this target gene rather than a non-specific cellular stimulation 
Figure 2. recMgIFN-γ purified by immobilised metal affinity chromatograph is mostly in a dimeric form. 
(a) SDS-PAGE followed by Coomassie staining for total protein detection (left) and detection of 6His-tagged 
proteins by Western Blot with an anti-6His monoclonal antibody (right). Lane 1: molecular weight marker (with 
sizes given to the left - sizes greater than 100 kDa were unreliable when constructing a standard curve); lane 2: 
flow-through (unbound proteins); lane 3: purified protein(s). (b) Size determination of purified recMgIFN-γ by 
analytical gel filtration analysis on a pre-calibrated Superdex 75 column. Protein peaks were detected at 230 nm 
(red) and 260 nm (blue), respectively.
Name of cell line Species Common name Organ/Tissue Cell type
NIH/3T3 Mus musculus House mouse Embryo Fibroblast
BVK168 Myodes glareolus Bank vole Kidney Epithelial-like
FMN-R Microtus arvalis Common vole Kidney Epithelial-like
AAL-R Apodemus agrarius Striped field mouse Lung Epithelial and fibroblast-like
Table 1. Rodent cell lines used in the present work.
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by bacterial contaminants. Taken together, these data demonstrated that recMgIFN-γ was capable of activating 
IFN-γ-dependent cellular responses in two cell lines of the two related vole species. However, in the same assay 
mouse IFN-γ was not active, corroborating the necessity for vole-specific IFN-γ.
Figure 3. Species-specific activity of recMgIFN-γ and mouse IFN-γ on different rodent cell lines. NIH/3T3, 
BVK168, FMN-R and AAL-R cells were tested and either left untreated as control (lower panel), stimulated 
for 1 h with recMgIFN-γ (200 ng/ml, upper panel) or mouse IFN-γ (200 U/ml, central panel). In each panel 
the following stainings are shown from left to right: phospho-Tyr701-STAT1 staining (green), DAPI staining 
(white) and overlay of the two signals. Activated phospho-STAT1 is indicated by nuclear translocation. Of 
note, minor background signal in the cytoplasma was observed in some control treated cells. A representative 
experiment of three replicates is shown. The scale bar represents 50 μm.
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recMgIFN-γ limits replication of vesicular stomatitis virus in bank vole cells. Testing for antiviral 
activity is a standard procedure for reporting biological activity of IFN-γ. BVK168 cells were previously shown 
to be permissive for a number of viruses including vesicular stomatitis virus (VSV)46 known to be highly suscep-
tible to IFN-γ treatment in murine cells47,48. We used a VSV replicon expressing luciferase (VSV*ΔG(FLuc)) as 
an easy to follow reporter via bioluminescence readout for measuring the IFN-γ effect on virus replication49. As 
shown in Fig. 5 we observed a drastic reduction of virus replication in VSV-infected BVK168 cells treated with 
1 ng/ml recMgIFN-γ and to a lesser extent with a lower concentration (0.2 ng/ml). The decrease in viral repli-
cation was comparable to that of virus-infected cells treated with a human hybrid type I interferon, IFN-αB/D, 
shown previously to inhibit virus replication50. No obvious antiviral effect was seen in cells treated with the control 
protein LEA. These results demonstrate that recMgIFN-γ possesses potent antiviral activity using this host-virus 
system. recMgIFN-γ antiviral potency was also tested on BVK168 cells infected with two other viruses, cowpox 
virus (CXPV) Brighton Red strain and murine gammaherpesvirus 68 (MHV68), but led to inconsistent inhibition 
results (preliminary data). This variability might be due to virus-specific defense mechanisms against host immune 
responses and/or to different cell type-specific responsiveness already documented in these families of viruses51–53.
Establishment of a bank vole reporter cell line responsive to recMgIFN-γ. An IFN-γ-responsive, 
sensitive reporter cell line would be advantageous for different purposes, like studying the influence of path-
ogens on JAK-STAT signalling54–56. Moreover, it would provide an easy test system for functional activity of 
recMgIFN-γ. To this end we established a BVK168 reporter cell line (named BVK-LucA) containing a stably 
integrated plasmid expressing firefly luciferase under the control of a minimal promoter with GAS sites (see 
Methods for details). As illustrated in Fig. 6, titration of recMgIFN-γ produced a sigmoidal dose-response in 
bioluminescence (6 to 8-fold) relative to either untreated, LEA or mouse IFN-γ-treated cells, which is typical 
for bio-indicator lines57. Within the linear range of the assay (between 20 and 0.02 ng/ml) recMgIFN-γ showed 
a dose-dependent decrease in signal strength, validating the BVK-LucA cell line as a useful tool to standardise 
recMgIFN-γ batches over a 100-fold concentration range. The non-linear dose-response with higher cytokine 
concentration (200 ng/ml) might be related to the recycling kinetics of the receptor subunit IFN-γR1, as reviewed 
before21, or by IFN-γR1 expression inhibition via an autocrine-mediated loop following persistent activation as 
already observed for type I interferon58.
The observed maximal-fold induction of firefly luciferase in BVK-LucA cells is well in the range of values from 
other stable GAS-dependent luciferase-expressing cell lines reported in the literature56,59. However, gene-specific 
differences in sequence, length and spacing of the palindromic GAS sequences have been shown to contrib-
ute to its affinity for STAT160. Thus, future analyses of vole genomes with regard to GAS elements of known, 
well-defined IFN-γ-regulated genes might lead to even more sensitive vole reporter cell lines.
Conclusions
Voles - of which M. glareolus and M. arvalis have been proven to be responsive to our recombinant IFN-γ - are 
epidemiologically important hosts for many pathogens and have been predicted to be reservoirs for one fourth 
of newly identified zoonoses3. For example, natural zoonotic reservoirs of the apicomplexan parasite Babesia 
microti, which can cause malaria-like infections in humans61, are various species of voles13. The influence of IFN-γ 
on B. microti infection has so far only been studied in inbred mouse strains after adaptation of the parasite strains 
to this unnatural host, and reported experiments eventually led to contradictory results62,63.
Figure 4. Dose-dependent induction of the expression of the target gene Irgb2-b1 by recMgIFN-γ in BVK168 
and FMN-R cells. Cells were treated for 24 h with either the negative control protein LEA (200 ng/ml), mouse 
IFN-γ (200 ng/ml) or recMgIFN-γ (10-fold dilution from 200 to 0.2 ng/ml). The reported mRNA fold induction 
is relative to untreated cells (set as 1; not shown) and normalised to Ywhaz for reference. Mean ± SEM (n = 3 
experiments, each with 2 replicates) are shown. Statistical analysis: One-way Anova followed by Dunnett’s 
multiple comparisons test (all against the LEA control protein). BVK168 (F(5,12) = 3.75, p = 0.0282) 
*p = 0.0322, FMN-R (F(5,12) = 21.34, p < 0.0001) ****p = 0.0001, ***p = 0.0004. Note that only statistically 
significant (p ≤ 0.05) differences were depicted in the figure.
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Voles are also a natural reservoir for the murid herpesvirus 4. Isolates of it (MHV-68) serve as models for 
human gammaherpesviruses64 and IFN-γ is known to control gene expression during MHV-68 latency in vivo 
in mice65. However, previous studies have pointed out various differences in pathogenesis between lab mice and 
natural hosts like A. sylvaticus and M. glareolus66,67. The provision of unlimited amounts of active recombinant 
vole IFN-γ reported here will allow the verification of its role in these and other vole-pathogen interactions where 
in the past house mice had to serve as surrogate and presumably sub-optimal hosts.
Figure 5. recMgIFN-γ limits replication of vesicular stomatitis virus in BVK168 cells. Cells infected with the 
VSV*ΔG(FLuc) strain expressing firefly luciferase were treated with either IFN-αB/D (5 ng/ml) as a known 
positive effector; with the negative control protein LEA; two concentrations of recMgIFN-γ (1 and 0.2 ng/ml), 
or left untreated as control (ctrl). The bioluminescence signal represents viral replication which is reported 
as percentage relative to untreated cells. Shown are mean ± SEM (n = 3 experiments, each with 2 replicates). 
Statistical analysis: One-way Anova (F(4, 10) = 37,24, p < 0.0001) followed by Sidak’s multiple comparisons test, 
**p = 0.0003, ***p < 0.0001.
Figure 6. Dose-dependent firefly luciferase activity after recMgIFN-γ induction in a bank vole reporter cell 
line. Bioluminescence assay on the reporter cell line BVK-LucA expressing the firefly luciferase gene under 
the control of a GAS promoter element. Cells were either left untreated (ctrl, not shown) or treated with the 
control protein LEA (200 ng/ml); mouse IFN-γ (200 ng/ml) or recMgIFN-γ (200 to 0.00002 ng/ml). The 
reported bioluminescence values are relative to untreated cells. Mean ± SEM (n = 4 experiments, each with 3 
replicates). Statistical analysis: One-way Anova (F(9, 30) = 76,16, p =  < 0.0001) followed by Dunnett’s multiple 
comparisons test (all against the LEA control protein). ***p = 0.0002, ****p ≤ 0.0001, relative to the control 
protein LEA. Note that only statistically significant (p ≤ 0.05) differences were depicted in the figure.
www.nature.com/scientificreports/
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Methods
Reagents. Mouse IFN-γ (20 µg; Peprotech) was reconstituted in 1 ml sterile water supplemented with 0.1% 
bovine serum albumin (BSA) and stored in aliquots at −20 °C (100 U = 20 ng). Mouse anti-6His-tag monoclonal 
antibody used for Western Blotting was from Linaris GmbH (Dossenheim, Germany) and used at a dilution 
of 0.5 µg/ml. For the immunofluorescent analysis a rabbit anti-phospho-STAT1 (Tyr701) monoclonal antibody 
(dilution 1:50) or rabbit polyclonal anti-phospho-STAT1 (Ser727) antibody (dilution 1:100; both Cell Signaling 
Technology) and an AlexaFluor 488-conjugated goat anti-rabbit secondary antibody (dilution 1:1,000; Abcam) 
were used.
Culture of cell lines. The following cell lines were used in this study: Mus musculus embryonic fibro-
blast cell line NIH/3T3, Myodes glareolus kidney cell line BVK16846, Microtus arvalis kidney cell line FMN-R 
and Apodemus agrarius lung cell line AAL-R (both Collection of Cell Lines in Veterinary Medicine (CCLV), 
Friedrich-Loeffler-Institut; Lenk, Reiche, Binder, Riebe and Ulrich, unpublished). All cell lines were maintained 
in Dulbecco’s modified Eagle’s medium (DMEM) with high glucose, stable glutamine and supplemented pyruvate 
(DMEM GlutaMAX, ThermoFischer Scientific), supplemented with 10% fetal bovine serum and antibiotics. Cells 
were passaged twice a week; BVK-168 and FMN-R cells were dissociated with StemPro Accutase (ThermoFischer 
Scientific), whereas trypsin/EDTA was used for AAL-R and NIH-3T3 cells.
Expression, purification and characterization of MgIFN-γ. The cDNA sequence of bank vole IFN-γ 
(GenBank HQ650825) was ordered codon-optimised for E. coli from GeneArt (ThermoFischer Scientific) 
and inserted with a C-terminal 6His-Tag-encoding sequence into a tetracycline-regulated expression vec-
tor (pASG-IBA33; IBA Göttingen, Germany) according to the supplier’s instructions. E. coli OmniMax 2T1R 
cells (Invitrogen) transformed with the resulting plasmid, named pASG33-MgIFN-γ, were used for expression. 
Cultures were grown in 2xYT medium at 37 °C to an OD600 of 1 before expression was induced by adding 200 
ng/ml doxycycline and incubated further for 3 h at 37 °C on an orbital shaker (300 rpm). Cells were lysed by 
ultrasonication in 25 mM Tris pH 7.5, 500 mM NaCl, 10 mM imidazole, supplemented with EDTA-free cOmplete 
Protease Inhibitor Cocktail (Roche Diagnostics). The cleared lysate was subjected to immobilised metal affinity 
chromatography (IMAC) on a Pierce HisPur Chromatography 1 ml cartridge (ThermoFischer Scientific), run on 
an Äkta Purifier FPLC system (GE Healthcare). Washing of and elution from the column were performed with 
the same buffer except that 50 and 500 mM imidazole, respectively, was added. Eluates were then subjected to 
gel filtration chromatography on a 5 ml Sephadex G25 column (GE Healthcare) for buffer exchange to PBS. The 
resulting protein solution was supplemented with 0.1% BSA and antibiotics and stored in aliquots at −80 °C.
SDS-PAGE and Western blotting was done on a 13% gel according to standard procedures, as described previ-
ously68. The prestained protein ladder PageRuler 10–180 kDa (ThermoFisher Scientific) was used.
Analytical gel filtration chromatography was performed using the FPLC system and 200 µl of purified 
recMgIFN-γ in PBS at room temperature on a calibrated Superdex 75 10/300 GL column (flow rate of 0.75 ml/
min) as described previously69. Protein extinction was recorded at 230 nm and 260 nm.
Plasmid pQE90S-LEA contains the coding sequence for T. gondii protein TGME49_076870 of 171 amino 
acids with a C-terminal 6His-tag and was purchased from GenExpress GmbH (Berlin, Germany). It was trans-
formed into E. coli OmniMax 2T1R cells, and expression was done as described above, except that for induction 
isopropyl-β-D-thiogalactopyranosid was added (final concentration 1 mM). Purification, desalting and storage 
of the recombinant LEA protein were done exactly as described for recMgIFN-γ.
Immunofluorescence Assay. BVK168, FMN-R, NIH/3T3 and AAL-R cells were grown on coverslips 
in 24-well plates and treated for 1 h with either mouse IFN-γ (200 U/ml) or recMgIFN-γ (200 ng/ml) or left 
untreated. Cells were then fixed with ice-cold methanol for 20 min, blocked for 1 h in 3% BSA solution, and 
stained with antibodies (see Reagents section). DNA was stained with 4′,6-Diamidine-2′-phenylindole dihydro-
chloride (1 ng/ml; Sigma-Aldrich). Coverslips were mounted on microscope slides with Fluoromount Aqueous 
Mounting Medium (Sigma-Aldrich). Samples were visualised using a Zeiss Axio Imager Z1/Apotome microscope 
(Zeiss). Images were acquired with a Zeiss AxioCam MRm camera using Zen 2012 Blue edition software and pro-
cessed using equal linear adjustments for all samples. Image analysis for co-localizations were done using ImageJ 
1.49 u and plugin “Blend Images” (http://imagej.nih.gov/ij/plugins/index.html).
Real-Time PCR. BVK168 and FMN-R cells were seeded into 24-well plates and at 70% confluency treated 
for 24 h with serial dilutions of recMgIFN-γ, mouse IFN-γ, LEA or left untreated. Then medium was aspi-
rated and cells were washed once with PBS. Total RNA was extracted with the RNeasy Plus RNA extraction 
kit after cell lysis with 350 µl RLT Plus buffer supplemented with β-mercaptoethanol (Qiagen) and reverse 
transcribed to cDNA with the PrimeScript RT-PCR Kit (Takara). PCR primers to amplify Irgb2-b1 (B2–3′-Fw 
5′-AAAGAAGAGCTTYTCACAG-3′ and B1-5′-Rev 5′-TCAGAGAGGATTTTRCTTTC-3′) were designed 
on available Microtus ochrogaster and M. musculus sequences (see Supplementary Methods). PCR primers to 
amplify the reference gene tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta 
gene (Ywhaz) were based on the homologous M. agrestis sequence reported previously45 (primer L-Ywhaz 
5′-GATGAAGCCATTGCTGAACTTGA-3′ and R-Ywhaz 5′-GCCGGTTAATTTTCCCCTCCT-3′). The ampli-
con extends over intron 4 with 1764 bp in M. ochrogaster, whereas the mRNA-derived product is 155 bp. These 
primers also bind to the respective M. musculus sequence (see Supplementary Methods). Real-Time PCR was 
performed with the Maxima SYBR Green/ROX kit (ThermoFisher Scientific) on an Applied Biosystem ABI 7500 
Real-Time PCR system. All reactions were run in duplicate with a no-template control to check for contamina-
tions. Each tube contained 1 μl of cDNA template (equivalent to 5 ng), 12.5 μl SYBR Green mix solution, 0.75 μl 
primer (75 μM each) and 10 μl H2O for a total reaction volume of 25 μl. The PCR conditions were 2 min at 50 °C, 
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10 min at 95 °C and 40 cycles of each 95° for 15 s and 60 °C for 1 min. Melting curve analysis was performed from 
60° to 95 °C at 1% ramp rate, with each step lasting 30 s to confirm presence of a single product and absence of 
primer dimers.
Establishment of the reporter cell line and luciferase assay. To allow selection for stable clones 
the blasticidin resistance selection marker (BsdR) gene was inserted into plasmid pGAS-Luc (Stratagene), 
which consists of a synthetic promoter that contains four direct repeats of a human-derived transcription rec-
ognition sequence for STAT1 (AGTTTCATATTACTCTAAATC)4 and a GAS followed by the firefly luciferase 
gene. The BsdR coding unit encompassed the SV40 promoter and origin, the Blasticidin resistance gene and 
the SV40 early polyadenylation site. It was amplified from pcDNA6-TR (Invitrogen) using primers Bsd-fwd 
5′-TCATGATAATAATGGTTTCTTAGACCAGACATGATAAGATACATTG-3′ and Bsd-rev 5′-ATTTCCC 
CGAAAAGTGCCACCTGACGAATGTGTGTCAGTTAGGG-3′. Cloning of the PCR product into 
ZraI-linearised pGAS-Luc was performed via the Seamless Ligation Cloning Extract (SLiCE) method as 
described in70 using E. coli strain JM109(DE3) (Promega) containing plasmid pKD4671 (Coli Genetic Stock 
Center #64672). The resulting plasmid, pGAS-Luc-Bsd, was sequenced over the insertion sites.
BVK168 cells were transfected with the plasmid pGAS-Luc-Bsd via the 25 kDa linear cationic polymer pol-
yethylenimine (PEI; Polysciences) in a molar ratio DNA:PEI of 1:500. Using Blasticidin selection (20 μg/ml, 
InvivoGen) a stably transfected BVK168 cell line was obtained and named BVK-LucA.
For the luciferase assay BVK-LucA cells were seeded into a 48-well plate. After 24 h either serial dilutions 
of recMgIFN-γ or mouse IFN-γ and LEA or DMEM as controls were added and incubation was continued for 
330 min at 37 °C as described previously59. The supernatant was removed, cells were washed once with PBS and 
65 μl of lysis reagent was added to each well. The lysates were assayed using the Dual-Luciferase Reporter Assay 
System (Promega). 20 µl of the cell lysate was mixed with 100 µl of reconstituted luciferase assay reagent in a 96 
well plate and the emitted light was measured in a Tristar LB 941 luminometer (Berthold).
Antiviral activity assay. For the antiviral activity assays BVK168 cells were seeded into 24-well plates 
and 6 h later treated with either recMgIFN-γ (1:200 and 1:1,000 dilutions, equivalent to 1 ng/ml and 0.2 ng/ml, 
respectively), with the control protein LEA (in concentration analogous to recMgIFN-γ) or left untreated for 16 h 
before infection. In addition, recombinant human IFN-αB/D known to be active on M. glareolus cell line was 
used as positive control (5 ng/ml)50. Next, the medium was aspirated and cells were inoculated with 0.5 MOI of 
VSV*ΔG(FLuc), a VSV glycoprotein-pseudotyped, propagation-incompetent VSV replicon, expressing firefly 
luciferase49. At 24 h post inoculation cells were lysed in 80 μl passive lysis buffer per well and luciferase activity 
determined in duplicates in a luminometer via the Dual-Luciferase Reporter Assay System (Promega).
Software used for sequence and statistical analyses. Sequences were searched by BLAST using 
the respective M. musculus protein sequences as query and downloaded from NCBI as detailed in SI Methods. 
Protein sequences were assembled from translated contigs, based on the respective BLAST results and compar-
ison with those of the GeneWise server (https://www.ebi.ac.uk/Tools/psa/genewise). Multiple sequence align-
ments were performed using MUSCLE 3.8.31 and visualised with JalView 2.10.172. The taxonomic species trees 
in Fig. 1 and Supplementary Fig. S1 (with species names as query) were obtained from https://www.ncbi.nlm.nih.
gov/Taxonomy/CommonTree/wwwcmt.cgi, visualised using the Evolview V2 server73 or FigTree 1.4.3 (http://
tree.bio.ed.ac.uk/software/figtree/) and modified with AffinityDesigner 1.5.3 software (Serif Ltd, UK).
Statistical analyses were performed using Prism 7 (GraphPad). Data were tested for normal distribution with 
the D’Agostino and Pearson normality test.
Data availability. All data generated or analysed during this study are included in the published article and 
its Supplementary Information files. Biological materials described herein are available upon request.
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